BACKGROUND/AIMS: Pancreatic endocrine tumors (PETs) occur sporadically, in association with the multiple endocrine neoplasia type 1 (MEN1) and the von Hippel-Lindau syndromes. CDK4 is central to the cell cycle control in pancreatic beta cells, and we have assessed whether CDK4 expression is deregulated in 18 human sporadic or familial PETs. METHODS: Real-time quantitative PCR, immunohistochemistry, DNA sequencing, and Western blot analysis were used. RESULTS: CDK4 mRNA was expressed in all PETs within the range of the arbitrary control. CDK4 protein was absent in normal pancreatic islets but distinctly expressed in all PETs as determined by immunohistochemistry. CDK4 expression was confirmed by Western blot analysis. No significant differences of CDK4 expression were observed between the groups of benign and malignant PETs or between tumors with or without MEN1 gene mutations. CDK4 expression was not due to gene amplification, and no mutations were identified in coding exons and RNA splice sites. c-Myc is known to be overexpressed in PETs and directly augments CDK4 expression in other cell types. Analysis of consecutive tissue sections for CDK4 and c-Myc showed overlapping homo- or heterogeneous immunostaining in all 18 PETs. CONCLUSION: We conclude that CDK4 and c-Myc is generally expressed in benign and malignant PETs, and regardless of MEN1 mutational status. Targeting of CDK4 may present an alternative to traditional chemotherapy of PETs in the future. (c) 2007 S. Karger AG, Basel.
BACKGROUND/AIMS: Pancreatic endocrine tumors (PETs) occur sporadically, in association with the multiple endocrine neoplasia type 1 (MEN1) and the von Hippel-Lindau syndromes. CDK4 is central to the cell cycle control in pancreatic beta cells, and we have assessed whether CDK4 expression is deregulated in 18 human sporadic or familial PETs. METHODS: Real-time quantitative PCR, immunohistochemistry, DNA sequencing, and Western blot analysis were used. RESULTS:CDK4 mRNA was expressed in all PETs within the range of the arbitrary control. CDK4 protein was absent in normal pancreatic islets but distinctly expressed in all PETs as determined by immunohistochemistry. CDK4 expression was confirmed by Western blot analysis. No significant differences of CDK4 expression were observed between the groups of benign and malignant PETs or between tumors with or without MEN1 gene mutations. CDK4 expression was not due to gene amplification, and no mutations were identified in coding exons and RNA splice sites. c-Myc is known to be overexpressed in PETs and directly augments CDK4 expression in other cell types. Analysis of consecutive tissue sections for CDK4 and c-Myc showed overlapping homo- or heterogeneous immunostaining in all 18 PETs. CONCLUSION: We conclude that CDK4 and c-Myc is generally expressed in benign and malignant PETs, and regardless of MEN1 mutational status. Targeting of CDK4 may present an alternative to traditional chemotherapy of PETs in the future. (c) 2007 S. Karger AG, Basel.
Authors: Christopher Koivisto; Gordon P Flake; Holly Kolenda-Roberts; Tiwanda Masinde; Grace E Kissling; Robert C Sills; Mark J Hoenerhoff Journal: Toxicol Pathol Date: 2012-04-03 Impact factor: 1.902
Authors: J Banerjee; R Pradhan; A Gupta; R Kumar; V Sahu; A D Upadhyay; P Chaterjee; S Dwivedi; S Dey; A B Dey Journal: Clin Transl Oncol Date: 2016-11-04 Impact factor: 3.405
Authors: Jordi Altirriba; Ainhoa García; Begoña Sánchez; Laura Haba; Sean Altekruse; Thomas Stratmann; Josep Antoni Bombí; Cristóbal Mezquita; Ramon Gomis; Conchi Mora Journal: Int J Cancer Date: 2011-08-29 Impact factor: 7.396